Coronavirus live updates: Bharat Biotech sets price for its Covaxin vaccine; Serum Institute defends the cost of its Covishield shot in the market.
Bharat Biotech noted that the manufacturing process was expensive due to low process yields, and that it was important to recover costs to invest in future R&D
The Andhra Pradesh government on Saturday placed an order for purchase of 40 mn doses each of Covaxin and Covishield for vaccinating 2.04 crore people in the 18-45 age group from May 1
Says the company would like to recover the costs incurred in clinical trials, and other things and reinvest the money into R&D to be ready for future pandemics
The B.1.617 or 'double mutant' Indian variant carries two mutations, including the L452R and E484Q
The Bharat Biotech candidate has also shown 70 per cent efficacy against asymptomatic infections, suggesting that it prevents transmission
In this podcast, we take a look at all those important updates related to coronavirus vaccine in a quick time
Could be priced at Rs 600-650/dose for institutional sales
"He has asked the industry to prioritise deliveries to meet the country's needs first and then focus on global supplies," said a person in the know, who did not wish to be named.
Firms work to secure raw material locally as imports remain a challenge
Govt conducts welcome course correction
States allowed to procure directly from manufacturers; open market supply permitted
Govt okays Rs 4,500 cr upfront payment for 300 mn doses
Some good moves but freer pricing needed
Bharat Biotech and 3 PSEs to ramp up Covaxin production capacity
Currently, 10 mn doses of the indigenous coronavirus vaccine are being produced every month, says govt
In a major step to ramp up vaccine production amid the Covid-19 second wave, the Centre has approved production of Corona vaccines from the Maharashtra government-owned Haffkine Institute in Mumbai
Last month, Uddhav Thackeray had sought central nod to manufacture Bharat Biotech's Covaxin at Haffkine Institute
Bharat Biotech is trying to ramp up capacities of Covaxin to 12 million doses per month by July, from the current 5 million doses per month
Russian Covid-19 vaccine granted restricted emergency-use authorisation in India